Yonsei University · Medicine
Professor Eun Seok Kang's research lab specializes in genetic and molecular mechanisms underlying metabolic diseases, particularly type 2 diabetes and post-transplant diabetes mellitus (PTDM). The lab investigates how genetic variations in key metabolic genes—such as PPARgamma2, adiponectin, and SLC30A8—affect therapeutic responses to drugs like rosiglitazone and influence glycemic control and disease progression. Their work bridges genetics, pharmacogenomics, and clinical outcomes to advance personalized medicine in diabetes care. The lab also explores the role of these genetic markers in transplant recipients, aiming to identify protective or risk-associated variants for better patient management.
Figures are computed from collected data and may differ slightly.
Patients with the Pro12Ala genotype in the PPARgamma2 gene had a better therapeutic response to rosiglitazone than did patients with the Pro12Pro genotype. The genetic variations in the PPARgamma2 gene can affect the response to rosiglitazone treatment in patients with type 2 diabetes mellitus.
These data suggest that genetic variations in the adiponectin gene can affect the rosiglitazone treatment response of the circulating adiponectin level and blood glucose control in type 2 diabetic patients.
These data provide evidence that the SLC30A8 rs13266634 gene variation is associated with protection from the development of PTDM in renal allograft recipients.
Open papers in the app to read, cite, and organize with AI.
